Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

GlobalData forecasts that the prostate cancer market is set to increase by 25% from $475.84 million in 2024 to $596.22 ...

The study involved 731 participants who were randomised to receive either tirzepatide or placebo. Credit: Africa Studio/Shutterstock. Eli Lilly has reported comprehensive outcomes from the Phase III ...

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

Spirovant has announced the commencement of its Phase I/II study with the first patient receiving a dose of SP-101 to treat ...

The two-day Oncology event will see industry experts from across the clinical trial space holding talks on subjects from AI ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

This research will inform the final design of the Exact Sciences Cancerguard test. Credit: Studio Romantic via Shutterstock. Exact Sciences has unveiled new findings from a case-control study ...

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.

At the OCT DACH conference, experts shared how EU laws, digitalisation, and more, are impacting trials in the DACH region and ...